Stock Alert: Quest Diagnostics Stock Up 7% On Consumer-Initiated Antibody Test Launch

Shares of Quest Diagnostics Inc. (DGX) are rising over 7% in pre-market today, after the company announced the launch of consumer-initiated COVID-19 antibody test through QuestDirect.

The company noted that beginning today, individuals can purchase COVID-19 antibody testing for themselves online, without visiting a doctor's office, through the company's consumer-initiated testing business QuestDirect.

Each test request is reviewed and, if appropriate, an order for testing is issued by a licensed physician, the company said. Individuals have the opportunity to speak with a licensed physician about their results.

On April 21, Quest announced the launch of its COVID-19 antibody test service for healthcare providers to order on behalf of patients.

The stock has been trading between $73.02 and $118.58 in the past one year, and closed Monday's trade at $116.02, up $9.40 or 8.82%. DGX is currently trading at $124.95, up $8.93 or 7.70% in the pre-market trading session.

For comments and feedback contact: editorial@rttnews.com

Business News

Looking to Invest in the Best Biotech Stocks? Subscribe to RTT Biotech Investor.
Follow RTT